Latest news with #ZydusLifesciences
Time of India
a day ago
- Business
- Time of India
Zydus Life's plans for cancer biosimilar hit a legal hurdle
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: The Delhi High Court has issued an interim injunction against Ahmedabad-based drug maker Zydus Lifesciences after a case filed by the US pharma giant Bristol Myers Squibb alleging patent infringement on its blockbuster anticancer drug Opdyta nivolumab ) branded as Opdivo in other restraining order comes as a setback for the Indian drug maker which was running clinical trials in India for the launch of the biosimilar versions of nivolumab. The earliest patent for the drug expires in India on May 2, 2026. The next hearing for the case is August 101-page order issued on July 18 by Justice Mini Pushkarna ruled that the defendants, and all others acting on its behalf, are restrained from manufacturing, using, selling, offering for sale, importing, exporting, advertising, or dealing in any biosimilar/similar biologic of nivolumab, the suit patent, during the pendency of the present suit. The order stated the plaintiffs shall suffer irreparable loss, in case the interim relief as prayed for, was not injections are one of the many latest generation immunotherapy drugs also known as checkpoint inhibitors increasingly used to treat several types of cancers including skin, lungs, kidneys, and Hodgkin lymphoma. It works by activating the body's T-cells or immune cells by targeting a protein called PD-1, thereby unleashing an attack on the cancer vials are sold in India for roughly '2 lakh but for patients who are part of the company's assistance or access programs, the drug is available at a slab-wise discounted the India data is not available, globally Bristol Myers Squibb recorded Opdivo sales of $9.3 billion in 2024. Indian companies have launched biosimilars at half the cost of those charged by their global in Indian patent laws told ET that the court has taken a view that stockpiling of a product during its active patent life amounts to infringement and to release it or flood the market is not legally valid."This opinion may have implications for the other ongoing disputes like the weight-loss drug semaglutide (branded Wegovy) case between Novo Nordisk and Dr. Reddy's Labs or Roche versus Natco for Risdiplam (drug used for a rare disease called spinal muscular atrophy or SMA) case," a senior lawyer petition from BMS noted that Zydus Lifesciences was conducting clinical trials for nivolumab and on its investigation found that the company had plans to launch it during the patent period. The Indian company, it said, had applied for a marketing approval with the central drug regulatory its part, lawyers on behalf of Zydus defended saying its product ZRC-3276 does not infringe upon the existing patents and is following the regulatory was represented by a battery of top lawyers including Harish Salve, Dushyant Dave, and Rajiv Nayar, while Squibb & Sons was represented by Sandeep Sethi, PS Raman, Amit Sibal and Pravin Anand, among others.
Economic Times
2 days ago
- Business
- Economic Times
Corporate actions this week: LIC, Hero Moto, 23 more stocks to have record dates for dividend. Do you own any?
India's largest life insurer Life Insurance Corporation (LIC), two-wheeler major Hero MotoCorp and pharma stocks like Novartis, Zydus Lifesciences and Lupin will be among 25 companies which will be holding their record dates for the purpose of dividend. Check if you own any of these stocks: ADVERTISEMENT Monday, July 21 It will be the ex-date and record date for dividends of: --Shree Cement: Final Dividend of Rs 60-- Thangamayil Jewellery: Final Dividend of Rs 12.50 ADVERTISEMENT Tuesday, July 22It will be the ex-date and record date for final dividend of Rs 100 Voltamp Transformers ADVERTISEMENT Wednesday, July 23It will be the ex-date and record date for dividends of: ADVERTISEMENT -- Aditya Birla Sun Life AMC: Dividend of Rs 24-- EL CID Investments: Final Dividend of Rs 25-- Novartis India: Final Dividend of Rs 25 ADVERTISEMENT -- Pidilite Industries: Final Dividend of Rs 20 Thursday, July 24 It will be the ex-date and record date for dividends of:-- Birlanu: Final Dividend of Rs 30 -- Fiem Industries: Final Dividend of Rs 30 -- Hero MotoCorp: Final Dividend of Rs 65-- Paushak: Final Dividend of Rs 20-- TCPL Packaging: Dividend of Rs 30 Friday, July 25 It will be the ex-date and record date for dividends of: -- 3M India: Dividend of Rs 535 -- Abbott India: Final Dividend of Rs 475 -- Akzo Nobel India: Final Dividend of Rs 30 -- Bharti Hexacom: Final Dividend of Rs 10-- Divis Laboratories: Final Dividend of Rs 30-- Fine Organic Industries: Final Dividend of Rs 11-- GOCL Corporation: Dividend Rs 10 -- ICRA: Final Dividend of Rs 60 -- Life Insurance Corporation of India (LIC): Final dividend of Rs 12-- Lupin: Final dividend of Rs 12 -- Thyrocare Technologies: Final Dividend of Rs 21 -- Timken India: Rs Final Dividend of Rs 36 -- Zydus Lifesciences: Final Dividend of Rs 11 (You can now subscribe to our ETMarkets WhatsApp channel)
Business Standard
6 days ago
- Business
- Business Standard
Zydus' Matoda facility completes Remote Regulatory Assessment of USFDA
Zydus Lifesciences announced that the USFDA conducted a Remote Regulatory Assessment (RRA) at Zydus' formulations manufacturing facility at Matoda in Gujarat for the Prior Approval Supplement (PAS) of Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg and 80 mg. At the closure, there were no observations noted, and the site was recommended for approval.
Time of India
6 days ago
- Business
- Time of India
Zydus Lifesciences shares in focus after USFDA nod for Celecoxib capsules
Zydus Lifesciences shares will be in focus after the company received final approval from the United States Food and Drug Administration ( USFDA ) for its Celecoxib capsules , a medication used for pain management. The approval covers Celecoxib capsules in strengths of 50 mg, 100 mg, 200 mg, and 400 mg, the company said in a regulatory filing on Tuesday. The drug will be manufactured at Zydus Lifesciences' facility in Ahmedabad. Celecoxib, sold under the brand name Celebrex, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, menstrual pain, and juvenile rheumatoid arthritis in children aged two years and above. According to IQVIA data, Celecoxib capsules recorded sales of $122.6 million in the US for the 12 months ending May 2025. With this approval, Zydus now has 428 ANDA approvals and has filed a total of 492 since it began the process in FY2003-04. Live Events In June, the USFDA issued two observations following an inspection conducted between June 9 and 18 at the company's oncology injectable manufacturing facility at SEZ 1 near Matoda, Ahmedabad. Zydus Lifesciences shares target price According to Trendlyne, the average target price for Zydus Lifesciences shares stands at Rs 967, indicating a potential downside of 1% from current levels. Of the 30 analysts tracking the stock, most have maintained a 'Hold' rating. Zydus Lifesciences shares performance Zydus Lifesciences shares are down 19% over the past year but have gained 63% over the last two years. The company's current market capitalisation is Rs 97,317 crore. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Economic Times
6 days ago
- Business
- Economic Times
Zydus Lifesciences shares in focus after USFDA nod for Celecoxib capsules
Zydus Lifesciences shares will be in focus after the company received final approval from the United States Food and Drug Administration (USFDA) for its Celecoxib capsules, a medication used for pain management. ADVERTISEMENT The approval covers Celecoxib capsules in strengths of 50 mg, 100 mg, 200 mg, and 400 mg, the company said in a regulatory filing on Tuesday. The drug will be manufactured at Zydus Lifesciences' facility in Ahmedabad. Celecoxib, sold under the brand name Celebrex, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, menstrual pain, and juvenile rheumatoid arthritis in children aged two years and above. According to IQVIA data, Celecoxib capsules recorded sales of $122.6 million in the US for the 12 months ending May this approval, Zydus now has 428 ANDA approvals and has filed a total of 492 since it began the process in June, the USFDA issued two observations following an inspection conducted between June 9 and 18 at the company's oncology injectable manufacturing facility at SEZ 1 near Matoda, Ahmedabad. ADVERTISEMENT According to Trendlyne, the average target price for Zydus Lifesciences shares stands at Rs 967, indicating a potential downside of 1% from current levels. Of the 30 analysts tracking the stock, most have maintained a 'Hold' rating. ADVERTISEMENT Zydus Lifesciences shares are down 19% over the past year but have gained 63% over the last two years. The company's current market capitalisation is Rs 97,317 crore. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)
